Victor Anusci / June 13, 2019
Stryker today announced that it is to invest over €200 million in Research, Development and Innovation (RD&I) projects at three of its five Cork facilities as it continues its vigorous innovation journey to deliver next generation products and services across its Medical Surgical, Orthopaedics and Neurotechnology and Spine offerings. The RD&I projects are supported by the Irish Government through IDA Ireland.
Last year, Stryker invested more than 6% of its global sales into research and development. This R&D programme will continue positioning the company at the leading edge of advances in medical technologies of the future and consists in investments in projects at its:
- AMagine Institute, which develops additive manufacturing products for three divisions, Spine, Craniomaxillofacial and Joint Replacement
- Neurovascular business, which develops stroke treatment products
- Instruments Innovation Centre, which designs, develops and commercializes new and innovative surgical devices across a range of surgical procedures
Announcing the news today, Stryker’s Spencer Stiles, Group President, Instruments, Neurotechnology & Spine said: “At Stryker we are committed to making healthcare better for our customers and their patients. Our mission is driven by a collaborative focus, leveraging the knowledge and experience of our talent across the globe. Our team in Ireland has built considerable Research and Development and New Product Development (NPD) capabilities through the partnership of multiple divisions, over the past twenty years, in an effort to serve multiple market segments. The continued growth and investment in Ireland is the result of many factors, inclusive of the Research, Development and Innovation (RD&I) support from IDA Ireland and the partnerships built with leading Irish universities and research centers. The support from Science Foundation Ireland (SFI) has allowed access to incredibly talented engineers and scientists based in Ireland.”
